Item 8.01. Other Events.

On January 19, 2023, Compass Therapeutics, Inc. (the "Company") issued a press release announcing positive interim data for its ongoing Phase 2 clinical trial assessing its clinical program, CTX-009, in combination with paclitaxel in advanced biliary tract cancers. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits




  99.1         Press Release issued on January 19, 2023 titled "Compass
             Therapeutics Announces that the Phase 2 Data of CTX-009 in
             Combination with Paclitaxel in Patients with Biliary Tract Cancers
             (BTC) will be Presented at the ASCO GI Cancers Symposium on January
             20, 2023"
104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

© Edgar Online, source Glimpses